Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Public ClinicalTrials.gov record NCT02292758. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized phase II trial studies how well irinotecan and cetuximab with or without bevacizumab work in treating patients with RAS wild-type colorectal cancer that has spread to other places in the body (locally advanced/metastatic) and cannot be removed by surgery. Irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as cetuximab and bevacizumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving irinotecan and cetuximab with or without bevacizumab may work betting in treating patients with colorectal cancer.
Study identification
- NCT ID
- NCT02292758
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab Biological
- Cetuximab Biological
- Irinotecan Drug
- Laboratory Biomarker Analysis Other
- Placebo Other
Biological · Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2014
- Primary completion
- Mar 19, 2019
- Completion
- Sep 26, 2019
- Last update posted
- Jan 30, 2022
2014 – 2019
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | — |
| Saint Luke's Mountain States Tumor Institute | Boise | Idaho | 83712 | — |
| Siouxland Regional Cancer Center | Sioux City | Iowa | 51101 | — |
| Cancer Center of Kansas - Wichita | Wichita | Kansas | 67214 | — |
| Ochsner Medical Center Jefferson | New Orleans | Louisiana | 70121 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Michigan Cancer Research Consortium NCORP | Ann Arbor | Michigan | 48106 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Heartland Regional Medical Center | Saint Joseph | Missouri | 64507 | — |
| Missouri Baptist Medical Center | St Louis | Missouri | 63131 | — |
| New Hampshire Oncology Hematology PA-Hooksett | Hooksett | New Hampshire | 03106 | — |
| State University of New York Upstate Medical University | Syracuse | New York | 13210 | — |
| Saint Vincent Regional Cancer Center CCOP | Green Bay | Wisconsin | 54301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02292758, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 30, 2022 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02292758 live on ClinicalTrials.gov.